Chirasuthat Phatcharawat, Chayavichitsilp Pamela
Division of Dermatology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Case Rep Dermatol. 2018 Aug 9;10(2):198-202. doi: 10.1159/000492172. eCollection 2018 May-Aug.
Atezolizumab is a humanized anti-PD-L1 immune checkpoint antibody that is currently used in many kinds of advanced carcinoma including metastatic non-small cell lung cancer. The cutaneous side effect profile reported only 20$ of the patients which had only mild maculopapular rash that required no treatment. There is no case report of anti-PD-L1 antibody-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) eruptions. To the best of our knowledge, there is no case report of atezolizumab-induced SJS or SJS/TEN induced by anti-PD-L1 immune checkpoint antibodies. We believe that our report will be useful to dermatologists who are consultants in the inpatient settings, as atezolizumab is an anti-neoplastic agent that has a potential to be used in multiple malignancies.
阿替利珠单抗是一种人源化抗程序性死亡配体1（PD-L1）免疫检查点抗体，目前用于多种晚期癌症，包括转移性非小细胞肺癌。报告显示，只有20%的患者出现皮肤副作用，且仅为无需治疗的轻度斑丘疹。尚无抗PD-L1抗体诱发史蒂文斯-约翰逊综合征（SJS）/中毒性表皮坏死松解症（TEN）皮疹的病例报告。据我们所知，尚无阿替利珠单抗诱发SJS或抗PD-L1免疫检查点抗体诱发SJS/TEN的病例报告。我们认为，我们的报告将对住院环境中的皮肤科顾问医生有用，因为阿替利珠单抗是一种有可能用于多种恶性肿瘤的抗肿瘤药物。
